non-clear cell kidney cancer

• 

Cabozantinib plus atezolizumab in non-clear cell kidney cancer

By Sharon Deveson Kell|2023-05-18T08:11:24+00:0018 May 2023|Drug treatments|

The results from an extended follow-up of the phase 1b [...]

Read More

Comments Off on Cabozantinib plus atezolizumab in non-clear cell kidney cancer

• 

Pembrolizumab plus axitinib for metastatic papillary and chromophobe kidney cancer

By Sharon Deveson Kell|2023-01-24T09:57:36+00:0024 Jan 2023|Drug treatments|

Non-clear cell kidney cancer is a group of different subtypes [...]

Read More

Comments Off on Pembrolizumab plus axitinib for metastatic papillary and chromophobe kidney cancer

• 

ESMO 2022: Pembrolizumab plus lenvatinib shows promise for non clear cell kidney cancer

By Sharon Deveson Kell|2022-10-25T07:38:41+00:0014 Sep 2022|Drug treatments|

The phase 2 KEYNOTE-B61 study was presented at the recent [...]

Read More

Comments Off on ESMO 2022: Pembrolizumab plus lenvatinib shows promise for non clear cell kidney cancer

• 

Samra Turajlic, Action Kidney Cancer trustees, talks about the forthcoming IKCS meeting

By Sharon Deveson Kell|2022-04-19T07:59:04+00:0019 Apr 2022|Drug treatments|

Samra Turajlic, Medical Oncologist, Action Kidney Cancer trustee, and member [...]

Read More

Comments Off on Samra Turajlic, Action Kidney Cancer trustees, talks about the forthcoming IKCS meeting

• 

International Kidney Cancer Symposium (IKCS) 2021

By Sharon Deveson Kell|2021-11-08T09:57:32+00:008 Nov 2021|Cancer news|

The International Kidney Cancer Symposium (IKCS) 2021 took place in [...]

Read More

Comments Off on International Kidney Cancer Symposium (IKCS) 2021

• 

Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma (RMC)

By Sharon Deveson Kell|2021-10-19T07:58:09+00:0019 Oct 2021|Subtypes of RCC|

Renal medullary carcinoma (RMC) is an extremely rare and aggressive [...]

Read More

Comments Off on Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma (RMC)

• 

Cabozantinib in combination with atezolizumab for advanced kidney cancer

By Sharon Deveson Kell|2021-10-01T08:04:29+00:001 Oct 2021|Drug treatments|

This phase Ib study reports the results of a combination [...]

Read More

Comments Off on Cabozantinib in combination with atezolizumab for advanced kidney cancer

• 

ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of non-clear cell kidney cancer

By Sharon Deveson Kell|2021-09-23T08:18:09+00:0023 Sep 2021|Drug treatments|

Non-clear cell RCC is about 20-25% of all RCC diagnoses [...]

Read More

Comments Off on ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of non-clear cell kidney cancer

• 

ASCO 2021: Nivolumab plus cabozanitinib for non-clear cell kidney cancer

By Robert|2021-07-07T12:48:55+00:008 Jun 2021|Drug treatments|

The cabozantinib/nivolumab combination has been shown to be effective at [...]

Read More

Comments Off on ASCO 2021: Nivolumab plus cabozanitinib for non-clear cell kidney cancer

• 

ASCO 2021: Cobozantinib plus nivolumab combination for non-clear cell kidney cancer

By Robert|2021-07-07T12:44:15+00:007 Jun 2021|Drug treatments|

The cabozantinib/nivolumab combination has been shown to be effective at [...]

Read More

Comments Off on ASCO 2021: Cobozantinib plus nivolumab combination for non-clear cell kidney cancer